Aldagen, UC-Davis Pact Aims to Develop Rx Candidates for Neural, Vascular Diseases | GenomeWeb
Biotech firm Aldagen and the University of California-Davis said this week that they plan to investigate if Aldagen’s adult stem-cell population can be used in a preclinical rat model of ischemic stroke, and if it can eventually play a role in creating drugs for other kinds of vascular or neurological disorders.
 
The collaboration will be the first to involve researchers at the UC-Davis Institute for Regenerative Cures, a new $62 million facility supported by the California Institute for Regenerative Medicine.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.